Table 2.
Concentration of N-EtFOSE and its metabolites in liver and serum from female Sprague Dawley rats.
| Tissue and treatment group | Liver (ppb) | Serum (ppb) | |||
|---|---|---|---|---|---|
| N-EtFOSE metabolites |
N-EtFOSE treatment group (n=9) |
Control animalsa (n=5) |
N-EtFOSE treatment group (n=9) |
Control animalsa (n=5) |
Liver: serum ratio |
| N-EtFOSEb | -c | -c | 177 ± 86 | n.d. | - |
| N-EtFOSAAb | 7,773 ± 2,413 | 8.0 ± 4.3 | 5,808 ± 2,132 | 4.1 ± 1.0 (n=3) | 1.3 |
| N-EtFOSAb | n.d. | n.d. | n.d. | n.d. | - |
| FOSEb | 10.0 ± 6.2 | n.d. | 1.6 ± 0.7 | n.d. | 6.4 |
| FOSAb | 4,470 ± 830 | 8.3 ± 6.0 | 441 ± 107 | 0.1 ± 0.1 (n=4) | 10.1 |
| PFOSd | 96,316 ± 11,452 | 64.7 ± 23.8 | 42,511 ± 11,365 | 8.1 ± 1.0 (n=4) | 2.3 |
Average of samples from the negative control (n=3) and the ciprofibrate (n=2) treatment group. One N-EtFOSE-contaminated animal in the ciprofibrate group was excluded from the data analysis. The number of samples above the LOQ is provided in parentheses where appropriate.
Adjusted for the respective matrix spike recovery in serum (N-EtFOSE = 67%; N-EtFOSAA = 159%; N-EtFOSA = 82%; FOSE = 96%; FOSA = 132%) and in the liver (N-EtFOSAA = 156±3%; N-EtFOSA = 19±2%; FOSE = 57±2%; FOSA = 98±3%). See the experimental part for additional details.
Corrected N-EtFOSE levels in the liver are not reported because of the poor recovery rate (2.5±1%); uncorrected N-EtFOSE levels group were low, with 4.6 ± 4.7 ppb in N-EtFOSE-treated animals and 7.8 ± 1.3 ppb in control animals.
Adjusted for the recovery of 13C4-PFOS.
n.d. = not detected.